Related Experiment Video

Updated: Dec 30, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.7K

Hyperuricemia: risk factor for thromboembolism in hypertrophic cardiomyopathy patients

Ziqiong Wang1, Hang Liao1, Xiaoping Chen1

  • 1Department of Cardiology, West China Hospital, Sichuan University, Sichuan, 37 Guo Xue Xiang, Chengdu, 610041, People's Republic of China.

Internal and Emergency Medicine
|January 16, 2020
PubMed

Insights

Hyperuricemia is a significant predictor of thromboembolism in hypertrophic cardiomyopathy (HCM) patients, particularly those with atrial fibrillation (AF) or non-obstructive HCM. This finding highlights the importance of managing uric acid levels in this population.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Hyperuricemia is a known cardiovascular disease risk factor.
  • Limited research exists on hyperuricemia's impact on thromboembolism in hypertrophic cardiomyopathy (HCM) patients.

Purpose of the Study:

  • To investigate the association between hyperuricemia and thromboembolic events in a retrospective cohort of adult HCM patients.

Main Methods:

  • Retrospective analysis of 447 adult HCM patients (December 2008 - May 2016).
  • Uric acid levels measured at baseline; hyperuricemia defined by sex-specific thresholds.
  • Thromboembolic events and potential confounders were analyzed during follow-up (1786.8 person-years).

Main Results:

  • 31 patients (6.9%) experienced thromboembolic events.
  • Hyperuricemia was associated with a higher incidence of thromboembolism (8.9% vs. 5.6%; adjusted HR 2.67, P=0.013).
  • Significant interactions were observed with atrial fibrillation (AF) and left ventricular outflow tract obstruction. Hyperuricemia strongly predicted thromboembolism in patients with AF (aHR 8.99) and non-obstructive HCM (aHR 6.89).

Conclusions:

  • Hyperuricemia is an independent predictor of future thromboembolism in HCM patients.
  • The association is particularly pronounced in HCM patients with AF and in those with non-obstructive disease.
  • Further research is warranted to confirm these findings and explore management strategies.

Keywords:
Atrial fibrillationHypertrophic cardiomyopathyHyperuricemiaThromboembolism

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

20.1K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
310
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
479
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
385
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
255
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
379